Article info
PDFPaper
Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases
- J Sonderholm, Department of Athletics, Georgetown University, Washington DC, USA; jorn13{at}gmail.com
Citation
Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases
Publication history
- Received June 12, 2008
- Revised December 23, 2008
- Accepted January 15, 2009
- First published April 30, 2009.
Online issue publication
April 30, 2009
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2009 BMJ Publishing Group Ltd and the Institute of Medical Ethics
Other content recommended for you
- Should rare diseases get special treatment?
- Patent pools: an idea whose time has come
- Don’t worry about the drug industry’s profits when considering a waiver on covid-19 intellectual property rights
- US incentive scheme for neglected diseases: a good idea gone wrong?
- New deal from the World Trade Organisation
- Ethical issues in funding research and development of drugs for neglected tropical diseases
- Public sector financial support for late stage discovery of new drugs in the United States: cohort study
- Ethical issues in funding orphan drug research and development
- Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most
- Prioritising neglected diseases related to poverty